Tag: Peter M Hecht


Cyclerion Therapeutics (NASDAQ: CYCN) Gains 30.16% Following Deal with Akebia for Praliciguat’s Development

Cyclerion Therapeutics (NASDAQ: CYCN) stock jumped 30.16% after the company revealed a series of insider purchases. CEO Peter M Hecht, director Terrance Mcguire, and top institutional shareholder Slate Path Capital purchased 1.9 million shares of the company in separate transactions on June 3 for a combined total value of $6.0 […]